These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 17125881)

  • 1. Pricing and reimbursement of in-patent drugs in seven European countries: a comparative analysis.
    Garattini L; Cornago D; De Compadri P
    Health Policy; 2007 Aug; 82(3):330-9. PubMed ID: 17125881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prices and distribution margins of in-patent drugs in pharmacy: a comparison in seven European countries.
    Garattini L; Motterlini N; Cornago D
    Health Policy; 2008 Mar; 85(3):305-13. PubMed ID: 17928092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmaceutical pricing and reimbursement reforms in Greece.
    Yfantopoulos J
    Eur J Health Econ; 2008 Feb; 9(1):87-97. PubMed ID: 17619920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. European perspective on the costs and cost-effectiveness of cancer therapies.
    Drummond MF; Mason AR
    J Clin Oncol; 2007 Jan; 25(2):191-5. PubMed ID: 17210939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The costs and benefits of regulations for reimbursement of new drugs.
    Lundkvist J; Jönsson B; Rehnberg C
    Health Policy; 2006 Dec; 79(2-3):337-44. PubMed ID: 16549221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Medical problems associated with the national reference pricing system in Hungary].
    Kerpel-Fronius S
    Orv Hetil; 2004 Apr; 145(17):913-8. PubMed ID: 15170969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reforming the Belgian market for orthotic braces: what can we learn from the international experience?
    Simoens S; De Coster S; Moldenaers I; Guillaume P; Depoorter A; Van den Steen D; Van de Sande S; Debruyne H; Ramaekers D; Lona M
    Health Policy; 2008 May; 86(2-3):195-203. PubMed ID: 18191275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Government regulation of pricing and reimbursement of prescription medicines: results of a recent multi-country review.
    Kingham R; Wheeler J
    Food Drug Law J; 2009; 64(1):101-14. PubMed ID: 19998574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pharmaceutical reference pricing in Germany: definition of therapeutic groups, price setting through regression procedure and effects].
    Stargardt T; Schreyögg J; Busse R
    Gesundheitswesen; 2005 Jul; 67(7):468-77. PubMed ID: 16103970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative approaches to pharmaceutical price regulation in the European Union.
    Mrazek MF
    Croat Med J; 2002 Aug; 43(4):453-61. PubMed ID: 12187524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Impact Reimbursement Act on the pharmaceutical market in Poland].
    Giermaziak W
    Pol Merkur Lekarski; 2014 Apr; 36(214):270-3. PubMed ID: 24868902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of generic reference pricing interventions in the statin market.
    Puig-Junoy J
    Health Policy; 2007 Nov; 84(1):14-29. PubMed ID: 17368619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of cross-reference pricing on pharmaceutical prices: manufacturers' pricing strategies and price regulation.
    Stargardt T; Schreyögg J
    Appl Health Econ Health Policy; 2006; 5(4):235-47. PubMed ID: 17249840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in external price referencing in Europe: a descriptive overview.
    Leopold C; Vogler S; Mantel-Teeuwisse AK; de Joncheere K; Leufkens HG; Laing R
    Health Policy; 2012 Jan; 104(1):50-60. PubMed ID: 22014843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Reimbursement of generics in Croatia: should more have been done?].
    Vukusić M
    Lijec Vjesn; 2010; 132(5-6):134-43. PubMed ID: 20677618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Off-patent drugs in Italy. A short-sighted view?
    Garattini L; Ghislandi S
    Eur J Health Econ; 2006 Mar; 7(1):79-83. PubMed ID: 16425040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conditional reimbursement within the Dutch drug policy.
    Niezen M; de Bont A; Stolk E; Eyck A; Niessen L; Stoevelaar H
    Health Policy; 2007 Nov; 84(1):39-50. PubMed ID: 17207886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Public administration and R&D localisation by pharmaceutical and biotech companies: a theoretical framework and the Italian case-study.
    Jommi C; Paruzzolo S
    Health Policy; 2007 Apr; 81(1):117-30. PubMed ID: 16824641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generic medicine pricing in Europe: current issues and future perspective.
    Simoens S
    J Med Econ; 2008; 11(1):171-5. PubMed ID: 19450118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of price regulation on the launch delay of new drugs--evidence from twenty-five major markets in the 1990s.
    Danzon PM; Wang YR; Wang L
    Health Econ; 2005 Mar; 14(3):269-92. PubMed ID: 15386651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.